Gasogul-DSR Capsule contains a combination of Domperidone 30 mg and Pantoprazole 40 mg, formulated to manage gastrointestinal disorders characterized by acid reflux, heartburn, and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea and vomiting. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related disorders including gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. The combination of these two agents in Gasogul-DSR Capsule offers a synergistic effect, addressing both the motility and acid secretion components of upper gastrointestinal conditions. This medication is indicated for patients experiencing symptoms of acid reflux accompanied by delayed gastric emptying or dyspepsia. Gasogul-DSR should be used under medical supervision, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with known hypersensitivity to either component, and potential drug interactions should be reviewed prior to initiation.